These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35490415)

  • 41. Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis.
    Bril F; Sanyal A; Cusi K
    Clin Liver Dis; 2023 May; 27(2):187-210. PubMed ID: 37024202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
    Nakajima T; Naito H
    Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
    Younossi Z; Stepanova M; Sanyal AJ; Harrison SA; Ratziu V; Abdelmalek MF; Diehl AM; Caldwell S; Shiffman ML; Schall RA; McColgan B; Subramanian GM; Myers RP; Muir A; Afdhal NH; Bosch J; Goodman Z
    J Hepatol; 2018 Dec; 69(6):1365-1370. PubMed ID: 30144554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity.
    Meneses D; Olveira A; Corripio R; Méndez MDC; Romero M; Calvo-Viñuelas I; Herranz L; Vicent D; de-Cos-Blanco AI
    Endocrinol Diabetes Nutr (Engl Ed); 2022 Mar; 69(3):178-188. PubMed ID: 35396116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease.
    Patton HM; Yates K; Unalp-Arida A; Behling CA; Huang TT; Rosenthal P; Sanyal AJ; Schwimmer JB; Lavine JE
    Am J Gastroenterol; 2010 Sep; 105(9):2093-102. PubMed ID: 20372110
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease.
    van den Berg EH; Gruppen EG; Ebtehaj S; Bakker SJL; Tietge UJF; Dullaart RPF
    Atherosclerosis; 2018 Oct; 277():21-27. PubMed ID: 30170220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
    Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
    Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Non-alcoholic fatty liver disease (NAFLD)].
    Rau M; Weiss J; Geier A
    Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
    Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The metabolic syndrome and chronic liver disease.
    Rosselli M; Lotersztajn S; Vizzutti F; Arena U; Pinzani M; Marra F
    Curr Pharm Des; 2014; 20(31):5010-24. PubMed ID: 24320032
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prevalence and risk factors of fatty liver in Portuguese adults.
    Leitão J; Carvalhana S; Cochicho J; Silva AP; Velasco F; Medeiros I; Alves AC; Bourbon M; Oliveiros B; Rodrigues V; Sousa R; Sampaio F; Carvalho A; Cortez-Pinto H
    Eur J Clin Invest; 2020 Jun; 50(6):e13235. PubMed ID: 32289180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity.
    Ooi GJ; Burton PR; Earnest A; Laurie C; Kemp WW; Nottle PD; McLean CA; Roberts SK; Brown WA
    Obes Surg; 2018 Feb; 28(2):427-436. PubMed ID: 28776153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgenetic alopecia: Traditional cardiovascular risk factors, metabolic syndrome, and component traits among Nigerian adults.
    Oiwoh SO; Akinboro AO; Olayemi O; Salawu AA; Olasode OA; Onayemi EO
    Niger J Clin Pract; 2023 Apr; 26(4):463-469. PubMed ID: 37203111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-Alcoholic Fatty Liver Disease.
    Brůha R
    Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
    Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.